Optimal Once-Daily Busulfan Administration in Pediatric Patients: A Simulation-Based Investigation of Intravenous Infusion Times

References

• Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309(22):1347–1353. doi:10.1056/NEJM198312013092202
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Boelens JJ, Bredius RG, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012;51(5):331–345. doi:10.2165/11598180-000000000-00000
   PubMed Web of Science ®Google Scholar
• Feng X, Wu Y, Zhang J, et al. Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis. BMC Pediatr. 2020;20(1):176. doi:10.1186/s12887-020-02028-6
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Lalmohamed A, van Reij EM, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3(11):e526–e536. doi:10.1016/S2352-3026(16)30114-4
   PubMed Web of Science ®Google Scholar
• Lee JW, Kang HJ, Lee SH, et al. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: Phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biol Blood Marrow Transplant. 2012;18(6):944–950. doi:10.1016/j.bbmt.2011.11.025
   PubMed Web of Science ®Google Scholar
• U FDA. Highlights of prescribing information, busulfex (Busulfan); 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf. Accessed March 12 2024
   Google Scholar
• Agency EM Product Information: busilvex; INN-busulfan; 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/busilvex-epar-product-information_en.pdf.Accessed March 12 2024
   Google Scholar
• Madden T, De lima M, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007;13(1):56–64. doi:10.1016/j.bbmt.2006.08.037
   PubMed Web of Science ®Google Scholar
• Kako S, Fujiwara S, Sato M, et al. Safety and efficacy of once-daily intravenous busulfan in allogeneic transplantation: a matched-pair analysis. Biol Blood Marrow Transplant. 2018;24(10):2139–2144. doi:10.1016/j.bbmt.2018.04.015
   PubMed Web of Science ®Google Scholar
• Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8(9):468–476. doi:10.1053/bbmt.2002.v8.pm12374451
   PubMed Web of Science ®Google Scholar
• de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104(3):857–864. doi:10.1182/blood-2004-02-0414
   PubMed Web of Science ®Google Scholar
• Ryu SG, Lee JH, Choi SJ, et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13(9):1095–1105. doi:10.1016/j.bbmt.2007.06.005
   PubMed Web of Science ®Google Scholar
• Kawazoe A, Funaki T, Kim S. Population pharmacokinetic analysis of busulfan in Japanese pediatric and adult hct patients. J Clin Pharmacol. 2018;58(9):1196–1204. doi:10.1002/jcph.1120
   PubMed Web of Science ®Google Scholar
• Lee JW, Kang HJ, Kim S, et al. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant. 2015;21(1):190–195. doi:10.1016/j.bbmt.2014.09.013
   PubMed Web of Science ®Google Scholar
• Buffery PJ, Allen KM, Chin PK, Moore GA, Barclay ML, Begg EJ. Thirteen years’ experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved? Ther Drug Monit. 2014;36(1):86–92. doi:10.1097/FTD.0b013e31829dc940
   PubMed Web of Science ®Google Scholar
• Yin J, Xiao Y, Zheng H, Zhang YC. Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients. Bone Marrow Transplant. 2015;50(5):696–705. doi:10.1038/bmt.2015.14
   PubMed Web of Science ®Google Scholar
• Rhee SJ, Lee JW, Yu KS, et al. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram. Am J Hematol. 2017;92(7):607–613. doi:10.1002/ajh.24734
   PubMed Web of Science ®Google Scholar
• Nguyen L, Fuller D, Lennon S, Leger F, Puozzo CIV. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004;33(10):979–987. doi:10.1038/sj.bmt.1704446
   PubMed Web of Science ®Google Scholar
• Booth BP, Rahman A, Dagher R, et al. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol. 2007;47(1):101–111. doi:10.1177/0091270006295789
   PubMed Web of Science ®Google Scholar
• Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc. 2003;78(5):589–598. doi:10.4065/78.5.589
   PubMed Web of Science ®Google Scholar
• Philippe M, Neely M, Rushing T, Bertrand Y, Bleyzac N, Goutelle S. Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children. Bone Marrow Transplant. 2019;54(3):448–457. doi:10.1038/s41409-018-0281-7
   PubMed Web of Science ®Google Scholar
• Geddes M, Kangarloo SB, Naveed F, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant. 2008;14(2):220–228. doi:10.1016/j.bbmt.2007.10.028
   PubMed Web of Science ®Google Scholar
• Michel G, Valteau-Couanet D, Gentet JC, et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer. 2012;58(1):90–97. doi:10.1002/pbc.22959
   PubMed Web of Science ®Google Scholar
• Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1–10. doi:10.3904/kjim.2009.24.1.1
   PubMedGoogle Scholar
• Ben Hassine K, Nava T, Theoret Y, et al. Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: results from a multicenter population pharmacokinetic study. CPT Pharmacometrics Syst Pharmacol. 2021;10(9):1043–1056. doi:10.1002/psp4.12683
   PubMedGoogle Scholar
• Bognar T, Bartelink IH, Egberts TCG, et al. Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2022;28(4):196–202. doi:10.1016/j.jtct.2022.01.013
   PubMedGoogle Scholar
• Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(9):486–492. doi:10.1053/bbmt.2002.v8.pm12374453
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Bredius RG, Ververs TT, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(1):88–98. doi:10.1016/j.bbmt.2007.09.015
   PubMed Web of Science ®Google Scholar